CCL2 and neoplasm: The underlying mechanisms for the modified MSC-exerted anticancer effects were described as an upregulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and enhanced stimulation of NK cells and cytotoxic T lymphocytes (CTL) in tumour tissues (51).